1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FCC77BA22493037E85257A95004EC11A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/manage-government-ecosystem-and-relevant-internal-groups-interactions?opendocument
18
19opendocument
20100.24.115.253
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Quality, Compliance and Regulatory » Government Affairs and Public Policy

Managing Healthcare Reform: Government Affairs, Public Policy, Managed Markets and Managing CMS and Internal Group Interactions to Cover the Government Ecosystem

ID: 5225


Features:

10 Info Graphics

19 Data Graphics

360+ Metrics

4 Narratives

2 Best Practices


Pages/Slides: 38


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Managing Healthcare Reform: Government Affairs, Public Policy, Managed Markets and Managing CMS and Internal Group Interactions to Cover the Government Ecosystem"


STUDY OVERVIEW

Public sector healthcare reform is creating an even greater need for functions like Government Affairs, Managed Markets, and Public Policy to effectively monitor and engage government agencies like the Centers for Medicare & Medicaid Services (CMS). Likewise, given how the government healthcare sector is an ecosystem of interconnected agencies and committees, it's important for relevant internal stakeholder to work together to coordinate public sector coverage.

Best Practices, LLC conducted this research to help leaders across key functions evaluate their approach to monitoring and engaging critical public payers. The study identifies how companies are better positioning themselves to manage the Washington ecosystem as well as interactions with relevant internal groups.

The study includes three segments: a Large Pharma Segment, a Mid-Cap Pharma Segment, and an Emerging Pharma segment.

KEY TOPICS

  • Intelligence Gathering: “The Capture” 
    • Being well-positioned to capture vital information From Within The Washington Ecosystem
  • Intelligence Translation: “The Interpretation”
    • Determining what  Information Coming from the Government Ecosystem means for brands, functions & business lines

SAMPLE KEY METRICS
  • Coverage of Federal Healthcare Groups
  • Resources Dedicated to CMS
  • Coverage Responsibility for CMS
  • Coverage of CMS Influencing Groups
  • Representation of CMS Influencing Groups
  • Responsibility for Monitoring and Managing Regional CMS offices
  • Key Responsibilities and Activities for Government Affairs, Policy, Managed Markets, Marketing
  • Managing Regional CMS Offices
  • Keeping Pace with Healthcare Change
  • U.S. Public Policy and Headquarters Interactions
  • Frequency of Group Interactions
  • Government Affairs & Policy Sub-Group Coordination Meetings
  • Improving Collaboration and Communication of Internal Groups

SAMPLE KEY FINDING
  • Engagement Responsibility for CMS: Government Affairs and Public Policy share responsibility for engaging with CMS. In the study, 58% of participants said GA has an engaging role with CMS while 53% said policy also has that responsibility. A number of companies – 37% - also noted Managed Markets engages with CMS, although that approach is more prevalent among Mid-Cap companies.
METHODOLOGY

Best Practices, LLC engaged 23 experienced executives, mainly in Government Affairs, Public Policy and Managed Markets, from 23 different pharmaceutical companies. In addition, deep-dive interviews were conducted with six participating companies to gather additional insights.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amylin; Astellas; AstraZeneca; Bayer; Boehringer Ingelheim; Cubist; Daiichi-Sankyo; GE Healthcare; Genentech; GlaxoSmithKline; IDEA Pharma; Integrated Diagnostics; Merck; Millenium; Novo Nordisk; ProStraken; Purdue; Sagent; Sanofi; Shionogi; Shire; Smith & Nephew

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.